/ TOP THINGS TO KNOW
A Drug Enforcement Administration judge canceled the marijuana rescheduling hearings that were set to begin next week amid an ongoing dispute about whether the agency actually supports the proposal it is supposed to be defending.
Earlier in the day, the Drug Enforcement Administration declined the opportunity to say if it supports the marijuana rescheduling proposal it is supposed to be defending in response to a recent legal filing that claimed the agency improperly conspired with opponents of the reform.
And the Drug Enforcement Administration judge slammed the agency for its “disobedience of an unequivocal directive” on marijuana rescheduling evidence for the now-canceled hearings, saying it is “unprecedented and astonishing.”
Virginia Gov. Glenn Youngkin (R) claimed during his State of the Commonwealth speech that legalizing marijuana sales leads to “significant negative impacts on children and adolescent health and safety” and other harms that “far exceed the perverse benefit of tax revenue.”
The U.S. Department of Agriculture and the Office of the U.S. Trade Representative appointed more hemp industry representatives to a federal trade advisory committee to help bolster efforts to promote U.S.-grown cannabis around the world.
Kentucky lawmakers filed a resolution calling on Congress to let medical cannabis patients possess guns, saying current policy causes “confusion, inconsistency and unnecessary legal risks” and that people shouldn’t “be forced to choose between accessing essential medical care and exercising their rights under the Second Amendment.”
The Dallas, Texas Police Department sent a memo directing officers to no longer make arrests or issue citations for possessing four ounces or less of marijuana in accordance with a voter-approved cannabis decriminalization ballot measure.
Bipartisan Colorado lawmakers introduced a bill to let doctors prescribe a form of psilocybin if the psychedelic is federally approved by the Food and Drug Administration.
A researcher discussed her new study showing that “in states where both medical and recreational marijuana are legal, fewer patients are filling prescriptions for medications used to treat anxiety.”
/ FEDERAL
The White House touted President Joe Biden’s marijuana actions in a social media post.
The Drug Enforcement Administration spotlighted reporting on teen drug use being at a record low.
/ STATES
Florida Gov. Ron DeSantis (R) again criticized Trulieve for funding an unsuccessful marijuana legalization ballot campaign at a press conference urging lawmakers to reform the citizen initiative process.
Texas’s agriculture commissioner spoke about efforts to restrict intoxicating hemp products.
A New York judge ruled that state and New York CIty officials’ actions against hemp stores were improper.
Massachusetts’s incoming top marijuana regulator spoke about how he plans to approach the job.
Alabama’s top medical cannabis regulator spoke about ongoing mediation to resolve litigation over business licensing.
California regulators are promoting disaster relief opportunities for marijuana businesses affected by recent wildfires.
Oklahoma regulators published a list of physicians willing to issue medical cannabis recommendations.
Minnesota regulators posted an FAQ about cannabis social equity grants.
Kentucky regulators will host a webinar for prospective medical cannabis patients on Wednesday.
/ INTERNATIONAL
Glasgow, Scotland is hosting the UK’s first safe consumption facility for illegal drugs.
The German Social Democratic Party made clear in an update to its election manifesto that it supports the country’s marijuana legalization law.
/ SCIENCE & HEALTH
A study concluded that “CBD can be incorporated into denture materials, enabling antibiotic-free dentures for preventing dental biofilms and reducing dental plaques.”
A study suggested “efficacy and safety of psilocybin in severe” treatment-resistant depression.
/ ADVOCACY, OPINION & ANALYSIS
Students for Sensible Drug Policy filed a post-trial brief in a Drug Enforcement Administration administrative court case concerning the agency’s proposed ban on two psychedelics.
CANNA PORTFOLIO –
JANUARY 15, 2025
VR CANNABIS MOVERS – JANUARY 15, 2025
DISCLAIMER:
WE ARE NOT FINANCIAL ADVISORS AND DO NOT PROVIDE FINANCIAL ADVICE
The website, LeibovitVRNewsletters.com, is published by LeibovitVRNewsletters LLC.
In using LeibovitVRnewsletters.com (a/k/a LeibovitVRNewsletters LLC) you agree to these Terms & Conditions governing the use of the service. These Terms & Conditions are subject to change without notice. We are publishers and are not registered as a broker-dealer or investment adviser either with the U.S. Securities and Exchange Commission or with any state securities authority.
All stocks and ETFs discussed are HYPOTHETICAL and not actual trades whose actual execution may differ markedly from prices posted on the website and in emails. This may be due internet connectivity, quote delays, data entry errors and other market conditions. Hypothetical or simulated performance results have certain inherent limitations as to liquidity and execution among other variables. PAST RESULTS ARE NOT NECESSARILY INDICATIVE OF FUTURE FORECASTING ACCURACY OR PROFITABLE TRADING RESULTS.
All investments are subject to risk, which should be considered on an individual basis before making any investment decision. We are not responsible for errors and omissions. These publications are intended solely for information and educational purposes only and the content within is not to be construed, under any circumstances, as an offer to buy or to sell or a solicitation to buy or sell or trade in any commodities or securities named within.
All commentary is provided for educational purposes only. This material is based upon information we consider reliable. However, accuracy is not guaranteed. Subscribers should always do their own investigation before investing in any security. Furthermore, you cannot be assured that your will profit or that any losses can or will be limited. It is important to know that no guarantee of any kind is implied nor possible where projections of future conditions in the markets are attempted.
Stocks and ETFs may be held by principals of LeibovitVRNewsletters LLC whose personal investment decisions including entry and exit points may differ from guidelines posted.
LeibovitVRNewsletters.com cannot and do not assess, verify or guarantee the suitability or profitability of any particular investment. You bear responsibility for your own investment research and decisions and should seek the advice of a qualified securities professional before making any investment. As an express condition of using this service and anytime after ending the service, you agree not to hold LeibovitVRNewsletters.com or any employees liable for trading losses, lost profits or other damages resulting from your use of information on the Site in any form (Web-based, email-based, or downloadable software), and you agree to indemnify and hold LeibovitVRNewsletters.com and its employees harmless from and against any and all claims, losses, liabilities, costs, and expenses (including but not limited to attorneys’ fees) arising from your violation of this agreement. This paragraph is not intended to limit rights available to you or to us that may be available under the federal securities laws.
For rights, permissions, subscription and customer service, contact the publisher at mark.vrtrader@gmail.com or call at 928-282-1275 or mail to 10632 N. Scottsdale Road B-426, Scottsdale, AZ 85254.
The Leibovit Volume Reversal, Volume Reversal and Leibovit VR are registered trademarks.
© Copyright 2025. All rights reserved.
